Anticoagulation Management in Special Patient Populations

Introduction to Apixaban Management

• Apixaban, a direct oral anticoagulant (DOAC), requires careful management in patients with impaired renal function, as it has approximately 25% renal clearance, according to the American College of Cardiology 1
• The standard dosing of apixaban is 5 mg twice daily, with dose reduction criteria including age ≥80 years, body weight ≤60 kg, or serum creatinine ≥1.5 mg/dL, at which point the dose should be reduced to 2.5 mg twice daily, as recommended by the American College of Cardiology and the European Heart Rhythm Association 2, 1, 3

Discontinuation and Resumption Guidelines

• For patients with normal renal function, apixaban should be discontinued 1 day before low-to-moderate bleeding risk procedures and 2 days before high bleeding risk procedures, according to the American College of Chest Physicians guidelines 4
• The European Society of Cardiology recommends discontinuing Eliquis at least 24 hours before low bleeding risk procedures and at least 48 hours before high bleeding risk procedures, with longer discontinuation times for patients with severe renal impairment 3
• The resumption time for DOACs after a procedure depends on the bleeding risk:

3

• For patients at high risk for thromboembolism, a reduced dose (2.5 mg twice daily) may be considered when initially resuming apixaban after high bleeding risk procedures, as suggested by the American College of Cardiology 1

Bleeding Risk Assessment and Management

• The European Society of Cardiology considers minor dental procedures, cataract or glaucoma surgery, endoscopy without biopsy, superficial surgery, and pacemaker or defibrillator implantation as low bleeding risk procedures, and major orthopedic surgery, extensive oral surgery, major cancer surgery, neurosurgery, and complex cardiovascular procedures as high bleeding risk procedures 3
• Minor dental procedures, including tooth extractions, are considered minimal bleeding risk procedures and do not require discontinuation of apixaban, according to the American College of Chest Physicians guidelines 4, 5
• Local hemostatic measures such as tranexamic acid mouthwash (10 mL of 5% solution) should be applied when continuing apixaban during tooth extraction to minimize bleeding risk, a recommendation that could be supported by guidelines from relevant medical societies 2, 5
• Monitoring for bleeding every 30 minutes initially after the procedure is crucial, especially in patients with factors that may increase bleeding risk, as emphasized by various clinical guidelines 2, 4, 5

Special Considerations

• Patients over 80 years old require careful monitoring due to increased bleeding risk, potentially reduced renal function affecting drug clearance, and higher stroke risk when off anticoagulation, as recommended by the French Working Group on Perioperative Hemostasis (GIHP) guidelines and the American College of Cardiology 2, 1
• Avoid overlapping anticoagulants, such as administering heparin and apixaban simultaneously, as it increases bleeding risk without additional benefit, as recommended by the American College of Cardiology, the European Heart Rhythm Association, and the American College of Chest Physicians 2, 1, 6
• Reversal with andexanet alfa or prothrombin complex concentrate (PCC) may be necessary for life-threatening bleeding, especially with intracranial hemorrhage, as recommended by the European Society of Cardiology and supported by other guidelines 7

Dose Adjustments and Interactions

• Dose adjustments may be needed with certain medications, including strong dual inhibitors of CYP3A4 and P-gp (e.g., ketoconazole), which require a 50% reduction in apixaban dose, and P-gp inhibitors, which require a 25% reduction in apixaban dose, as recommended by the European Respiratory Review 8